Clinical Trial VICCNCPED10100


An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

Principal Investigator(s)

Richard Ho


  • Protocol No. VICCNCPED10100
  • Open Date: 02/22/2010
  • Staging: Phase III
  • Age Group: Children
  • Scope: National
  • Objective: The primary objective of this study is to evaluate the safety of romiplostim as a long-term treatment in pediatric thrombocytopenic subjects with immune (idiopathic) thrombocytopenic purpura.
  • Disease Sites: Pediatrics; Benign Hematologic
  • Therapies: Therapy (NOS)
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00508820
  • Secondary Protocol No: 20090340



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.